After at least one prior line of therapy,
Unlock the power of BLENREP in combination therapy
For relapsed or refractory multiple myeloma
PrBLENREP (belantamab mafodotin for injection) is indicated in combination with1:
- bortezomib and dexamethasone (BVd) for the treatment of adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy
- pomalidomide and dexamethasone (BPd) for the treatment of adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including lenalidomide
BLENREP combination therapy was evaluated across key efficacy endpoints in two pivotal Phase 3 trials1:
- Progression-free survival (PFS)
- Overall survival (OS)
- Response rates and minimal residual disease
-
Mechanism of action
BLENREP is a BCMA-targeted antibody-drug conjugate with a dual mechanism in multiple myeloma cells.
Explore the mechanism -
Efficacy data
BLENREP combination therapy was evaluated in DREAMM-7 and DREAMM-8 — two pivotal Phase 3 trials.
Explore the efficacy data -
Safety data
Review the BLENREP safety profile, eye-related side effects, and supportive eye-care management.
Explore the safety profile
Patient profiles
Three fictitious patient profiles illustrating BLENREP combination therapy considerations.*
-
Meet Bryant*
59-year-old male · Diagnosed with MM 5 years ago.
Learn more -
Meet Bonnie*
67-year-old female · Diagnosed with MM 4 years ago.
Learn more -
Meet Beatrice*
70-year-old female · Diagnosed with MM 8 years ago.
Learn more
*Fictitious patients. May not be representative of all patients.
Consider BLENREP for your eligible patients
Need more information about BLENREP?
Reference
- Current BLENREP Product Monograph. GlaxoSmithKline Inc.